

## References

### I-173

1. Pharmacy Drug Coverage Policy Manual. North Dakota Department of Health and Human Services. Medical Services Division. <http://www.hidesigns.com/ndmedicaid/pdl/>
2. Nagase M, Yamamoto Y, Miyazaki Y, Yoshino H. Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration. *Redox Rep.* 2016 May;21(3):104-1.
3. Erratum in Diagnostic criteria in amyotrophic lateral sclerosis: A multicenter prospective study. [*Neurology.* 2017]
4. Petrov D, Mansfield C, Moussy A, Hermine O. ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment? *Frontiers in Aging Neuroscience.* Review, March 2017.
5. Okada M, Yamashita S, Ueyama H, Ishizaki M, Maeda Y, Ando Y. Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis. *eNeurologicalSci.*2018;11:11-14.
6. Radicava (edaravone), for intravenous use [package insert]. Mitsubishi Tanabe Pharma Corporation. Jersey City, NJ. Revised.03/2021.
7. Brooks BR, Jorgenson JA, Newhouse BJ, Shefner JM, Agnese W. Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy—a roundtable discussion. *Am J Manag Care.* 2018;24:175-186.
8. Andrews JA, Meng L, Kulke SF, Rudnicki SA, Wolff AA, Bozik ME, et al. Association between decline in slow vital capacity and respiratory insufficiency, use of assisted ventilation, tracheostomy, or death in patients with amyotrophic lateral sclerosis. *JAMA Neurology.* 2018;75(1):58-64.
9. U.S. Department of Health and Human Services, National Institutes of Health, National Center for Advancing Translation Sciences. (2019). Genetic and Rare diseases (GARD) Information. Progressive bulbar palsy.
10. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).
11. Kalin A, Medina-Paraiso E, Ishizaki K, et al. A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies. *Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration.* October 2017:71-79.
12. Thakore NJ, Lapin BR, Pioro EP, Pooled Resource Open-Access ALS Clinical Trials Consortium, Pooled Resource Open-Access ALS Clinical Trials Consortium. Trajectories of impairment in amyotrophic lateral sclerosis:

- Insights from the Pooled Resource Open-Access ALS Clinical Trials cohort. *Muscle & Nerve*. 2018;57(6):937-945.
13. Clinical Pharmacology Compendia [database online].2021. Tampa FL: Gold Standard, Inc. Edaravone.
  14. Micromedex®Solutions Compendia.2021.Edaravone.
  15. Shefner J, Heiman-Patterson T, Piro EP, Wiedau-Pazos M, et al. Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19). *Muscle & Nerve*. 2020;61:218–242.
  16. Edaravone. Lexi-Drugs. Hudson, OH: Lexicomp, 2021. 17.\
  17. Edaravone In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated 11/20/2017